BIOPATCH® Protective Disk with CHG

#1 selling CHG dressing¹
1A CDC recommendation²
Prepping the skin isn’t enough

Within hours of thorough antiseptic application, resident bacteria recolonize on the skin’s surface.\(^6\)

### The problem

**CLABSIs are the costliest healthcare-associated infections**\(^3\)

**COSTLY**
- At over $45,000 per patient, CLABSI is the costliest healthcare-related infection in the US\(^3\)
- Annual estimated cost of more than $1 billion\(^1\)

An estimated 65%-70% of CLABSIs are **preventable**\(^8\)

60% of CRBSIs originate from the patient’s own skin\(^2\)

### Prepping the skin isn’t enough

Within hours of thorough antiseptic application, resident bacteria recolonize on the skin’s surface.\(^6\)

### The solution

**BIOPATCH® Protective Disk with CHG**

Sustained antimicrobial action over 7 days through proprietary delivery technology\(^9\)

Continuous release of CHG and 360° protection for ongoing antisepsis between dressing changes

BIOPATCH Disk CHG release rate over 7 days\(^6\)

For use with both vascular and nonvascular percutaneous devices

**Backed by evidence**

The clinical data on BIOPATCH Disk speaks for itself

BIOPATCH Disk has a cleared indication to reduce the incidence of CRBSIs, local infections, and skin colonization in patients with central venous and arterial catheters\(^1\)

Only BIOPATCH Disk has over 25 years of extensive clinical experience,\(^12,13-17\):
- 15 randomized controlled trials
- 13 Level II forms of evidence
- 6 Level III forms of evidence

**For use with both vascular and nonvascular percutaneous devices**

**Hear from the experts**

**The Joint Commission**
- Use proven guidelines to prevent infection of the blood from central lines\(^2\)

**Centers for Disease Control and Prevention**
- For patients aged 18 years and older: Chlorhexidine-impregnated sponge dressing with an FDA cleared label that specifies a clinical indication for reducing CRBSI in CLABSI are recommended to replace the current idea of antiseptics in non-drummed central venous catheters. Category 1A - Strongly Recommended and strongly supported\(^18\)

**Infection Control & Hospital Epidemiology**
- Use chlorhexidine-impregnated sponge dressing for CVADs to reduce infection risk when the extraluminal route is the primary source of infection\(^19\)

**American Association of Critical-Care Nurses**
- Apply chlorhexidine-impregnated sponge dressing to decrease the risk of bacterial growth at the insertion site\(^20\)

**Oncology Nursing Society**
- Use CHG-impregnated sponge dressing for all CVADs, including specialty catheters in patients older than 2 months of age. Emerging data suggests that the role of catheter-related bloodstream infections from peripheral catheters may be higher than once thought\(^21\)

**Association for Professionals in Infection Control and Epidemiology (APIC)**
- The risk for infection is present during the entire dwell time of the catheter. The use of a post-insertion care bundle was associated with a significant reduction\(^22\)

**All types of lines pose a risk of infection. All should receive preventive measures.**

Recommendation from a systematic review by Drs. Dennis Maki, Daniel Kluger, and Christopher Crinich\(^7\)
**Removal with BIOPATCH® Disk with CHG is a simple, one-step process**—with no saline or alcohol swabs needed

**ORDER CODE**

<table>
<thead>
<tr>
<th>Size</th>
<th>4150</th>
<th>4151</th>
<th>4152</th>
</tr>
</thead>
<tbody>
<tr>
<td>½ disc (2.5cm)</td>
<td>¾ disc (19cm)</td>
<td>1 disc (2.5cm)</td>
<td></td>
</tr>
<tr>
<td>w/40mm center hole</td>
<td>w/15mm center hole</td>
<td>w/70mm center hole</td>
<td></td>
</tr>
</tbody>
</table>

**FRENCH SIZE RANGE**

<table>
<thead>
<tr>
<th>Common Uses</th>
<th>6-12Fr</th>
<th>&lt;6Fr</th>
<th>13-20Fr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Lines PICC</td>
<td>Peripheral IVs Huber Needles (ports) Arterial Lines</td>
<td>Dialysis Catheters Drains Sheaths Cordis Catheters VAD Drive Lines</td>
<td></td>
</tr>
</tbody>
</table>

**QUANTITY PER CASE**

<table>
<thead>
<tr>
<th>10/box</th>
<th>4 boxes/case, 40</th>
</tr>
</thead>
<tbody>
<tr>
<td>92 mg</td>
<td>52.5 mg 86.8 mg</td>
</tr>
</tbody>
</table>

For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to the full package insert.